Cell Free DNA as a Diagnostic and Prognostic Marker for Cardiovascular Diseases

Iuliia A Polina 1, Daria V Ilatovskaya 1, Kristine Y DeLeon-Pennell 2

Affiliations

PMID: 31978408
DOI: 10.1016/j.cca.2020.01.013

Abstract

Release of cell free DNA (cfDNA) from damaged or dead cells routinely occurs in normal physiology. Recently, cfDNA has emerged as an essential biomarker in cardiovascular disease (CVD) of potential prognostic and diagnostic significance. Within the last decade, significant research efforts have been devoted to uncovering the mechanisms mediating cfDNA release and its outcome-predicting ability. The current review focuses on the pathways for cfDNA release in myocardial infarction, heart failure and hypertension, and discusses implementation of cfDNA monitoring to assess the overall development of these disease states and predict future complications.

Keywords: Cardiovascular disease; Inflammation; MMPs; cfDNA.

Published by Elsevier B.V.

Similar articles

Circulating Cell-Free DNA: An Up-Coming Molecular Marker in Exercise Physiology
S Breitbach et al. Sports Med 42 (7), 565-86. 2012. PMID 22694348. - Review
The phenomenon of circulating cell-free DNA (cfDNA) concentrations is of importance for many biomedical disciplines including the field of exercise physiology. Increases …
Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases
B Duvvuri et al. Front Immunol 10, 502. 2019. PMID 30941136. - Review
Endogenous DNA is primarily found intracellularly in nuclei and mitochondria. However, extracellular, cell-free (cf) DNA, has been observed in several pathological condit …
Correlations of Circulating Cell-Free DNA With Clinical Manifestations in Acute Myocardial Infarction
J Xie et al. Am J Med Sci 356 (2), 121-129. Aug 2018. PMID 30219153.
Measuring cfDNA in patients with CVD offers an alternative approach to monitor the disease and has potential clinical applications to identify high-risk individuals.
Plasma Total Cell-Free DNA (cfDNA) Is a Surrogate Biomarker for Tumour Burden and a Prognostic Biomarker for Survival in Metastatic Melanoma Patients
S Valpione et al. Eur J Cancer 88, 1-9. Jan 2018. PMID 29175734.
We have demonstrated that cfDNA is a surrogate marker of tumour burden in metastatic melanoma patients, and that it is prognostic for overall survival.
Clinical Significance of Cell-Free DNA as a Prognostic Biomarker in Patients With Diffuse Large B-cell Lymphoma
M Eskandari et al. Blood Res 54 (2), 114-119. Jun 2019. PMID 31309089.
Quantification of cfDNA with qPCR at the time of diagnosis may allow identification of patients with high cfDNA concentration, which correlates with aggressive clinical o …